🎉 Read a new article on Monday! 📄 Title: Eosinophilic inflammation in bronchiectasis: a wide-open field for future research 🔗https://lnkd.in/gTSbzTis 🔖 Bronchiectasis is a heterogeneous chronic lung disease, characterised by irreversible dilatation of the airways and attributed to a wide spectrum of other underlying conditions, usually underdiagnosed and inadequately treated with a high burden for both the patients and the healthcare system. The way bronchiectasis is viewed by physicians has drastically changed over the last decades, with the topic of eosinophilia in the context of the disease being one of the substantially highlighted. Eosinophilia was traditionally considered as a means for distinguishing bronchiectasis from asthma, whereas bronchiectasis was primarily associated with neutrophilic inflammation. However, eosinophilic bronchiectasis is nowadays identified as a distinct disease endotype and is associated with a specific clinical course and response to treatment. #Bronchiectasis #eosinophil #eosinophilicinflammation
Exploration of Asthma & Allergy’s Post
More Relevant Posts
-
🎉 Start your week with a must-read article! 📄 Title: Eosinophilic inflammation in bronchiectasis: a wide-open field for future research 🔗 https://lnkd.in/gTSbzTis 🔖 Bronchiectasis, a chronic lung disease often underdiagnosed, is now viewed differently by physicians. Eosinophilic bronchiectasis, once seen as distinct from asthma, is now recognized as its own endotype with specific clinical traits and treatment responses. #Bronchiectasis #Eosinophil #EosinophilicInflammation
🎉 Read a new article on Monday! 📄 Title: Eosinophilic inflammation in bronchiectasis: a wide-open field for future research 🔗https://lnkd.in/gTSbzTis 🔖 Bronchiectasis is a heterogeneous chronic lung disease, characterised by irreversible dilatation of the airways and attributed to a wide spectrum of other underlying conditions, usually underdiagnosed and inadequately treated with a high burden for both the patients and the healthcare system. The way bronchiectasis is viewed by physicians has drastically changed over the last decades, with the topic of eosinophilia in the context of the disease being one of the substantially highlighted. Eosinophilia was traditionally considered as a means for distinguishing bronchiectasis from asthma, whereas bronchiectasis was primarily associated with neutrophilic inflammation. However, eosinophilic bronchiectasis is nowadays identified as a distinct disease endotype and is associated with a specific clinical course and response to treatment. #Bronchiectasis #eosinophil #eosinophilicinflammation
-
Did you know that more than 95% of rare diseases are still without an FDA-approved treatment? 🧬 On Rare Disease Day, this February 29th—a date as unique as the patients we aim to serve—we spotlight the urgent need for research and the vital support required by patients and their families. At PVP, we’re at the forefront of partnering with those dedicated to enhancing patient outcomes for conditions like Pulmonary Arterial Hypertension, Gastroparesis, and Cystic Fibrosis. Our mission? To bridge the gap between patient insights and clinical trial design, ensuring groundbreaking treatments reach those in desperate need. Join us in amplifying the voices of the rare disease community. Together, we can transform 'rare' into 'recognized.' 🤝 Learn more about Rare Disease Day here: https://lnkd.in/e2nh5pd #RareDiseaseDay #clinicaltrials
-
-
October 20th is International Mastocytosis and Mast Cell Diseases Awareness Day Systemic Mastocytosis (SM) is a rare and chronic disorder where abnormal mast cells accumulate in various tissues, affecting organs such as the skin, liver, and bones. This can lead to a wide range of symptoms, from skin reactions and gastrointestinal issues to more severe complications. For patients, the journey to diagnosis and management can be complex and overwhelming. At Rare Disease Advisor, we are committed to supporting both patients and healthcare professionals with up-to-date resources, educational materials, and expert insights to navigate this challenging condition. Whether you're seeking information on diagnosis, treatment options, or daily management, we're here to help. Visit our website for valuable resources tailored to your needs. ➡️ Healthcare professionals click here: https://lnkd.in/eNss9Ymb ➡️ Patients click here: https://lnkd.in/eXG9WU_W #MastocytosisAwareness #MastCellDiseases #RareDiseases #SystemicMastocytosis
-
-
October 26 markets the 4th #WorldAmyloidosisDay Amyloidosis is a rare and complex disease that affects organs including the heart, kidneys and peripheral nervous system. It’s caused by an abnormal build-up of proteins and often goes undiagnosed for long periods of time due to its rarity and complex presentation. By raising awareness of this rare disease, it is our hope that patients can get earlier diagnoses and better treatment outcomes. World Amyloidosis Day 2024: October 26 - Amyloidosis Alliance https://lnkd.in/eG9JA-pe
-
-
#NEWS: The results of our Phase II study AIRLEAF®, investigating our Cathepsin C inhibitor as potential treatment for adults with bronchiectasis, have been published in the in European Respiratory Journal. Bronchiectasis is the third most common chronic lung disease worldwide. It is associated with significant mortality that is primarily linked to pulmonary exacerbations. There is a high unmet need for a novel bronchiectasis treatment due to poor prognosis. Learn more here about bronchiectasis: https://lnkd.in/ewE3s3Hf
-
-
In the recent MEDcast, Saakshi Khattri, MD, Jennifer Soung, MD, and Kostas N. Botsoglou, MD, explore evidence-based strategies to decelerate the progression of psoriasis and psoriatic arthritis, aiming to optimize patient outcomes and enhance long-term disease management. Watch now: https://bit.ly/4gAsD2u
-
-
Cardiologist Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the limitations and challenges within pulmonary arterial hypertension (PAH) treatment strategies, including the adoption of new therapies and the impact of emerging treatments on patient outcomes, quality of life, and long-term disease management. Watch the episode to learn more about the future of PAH: https://bit.ly/4be1QWh #hypertension
-
-
Pulmonary hypertension is a difficult disease to diagnose—many of its symptoms, like shortness of breath, fatigue, and chest pain, are often mistaken as symptoms of other medical conditions. It's even harder to spot when complicated by interstitial lung disease (ILD), a heterogenous condition that shares many symptoms with #PH. At least 9% of PH patients developed their disease due to chronic lung disease, and between 32% and 85% of pulmonary fibrosis patients have pulmonary hypertension. Join Pulmovant this #PHawarenessmonth in spreading awareness of #PH-ILD to help patients receive the accurate diagnosis they deserve. Learn more about Pulmovant’s efforts to bring potential new treatment options to PH-ILD here: https://lnkd.in/egvUNR2j
-
-
Given the rising burden of diabetes in India & the intricate association of T2DM with CVDs, this is a vital step in empowering clinicians with a handy, lab concordant solution to drive early screening of T2DM patients who might be at the risk of heart failure!
Thrilled to announce the launch of our point-of-care NT-proBNP test. Designed to revolutionise patient care by screening type 2 diabetes patients at risk of cardiovascular diseases like heart failure, this innovation aims to provide faster, more efficient diagnosis and disease management. Kudos to the team for bringing testing closer to clinics! To learn more about this exciting development, read the full story on ThePrint https://lnkd.in/dMpacBpm #Roche | #ValueOfDiagnostics | #Diabetes | #HeartFailure
-
-
Global Head of Respiratory, Allergy, and Infectious Disease Product Development at Genentech
As we approach World COPD Day, it's important to recognise that COPD is the third leading cause of death worldwide, unfortunately, so many people remain undiagnosed. COPD involves a complex interplay of inflammatory pathways driven by distinct types of inflammation — Type 1, 2, and 3 — each linked to unique immune responses that cause persistent inflammation in the airways and lung tissue. There remains a large unmet treatment need that addresses these underlying pathways. COPD is also often not diagnosed until the disease is more advanced due to an under-recognition of respiratory symptoms. Early diagnosis is crucial for improving patient outcomes, slowing disease progression, and reducing burdens on healthcare systems. Read more here: https://lnkd.in/gqV9jXzB
-
